<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04798326</url>
  </required_header>
  <id_info>
    <org_study_id>MW032-2019-CP101</org_study_id>
    <nct_id>NCT04798326</nct_id>
  </id_info>
  <brief_title>Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults</brief_title>
  <acronym>MW032</acronym>
  <official_title>A Single Center, Randomized, Double-blind , Single-dose, and Parallel Group Study to Compare the Pharmacokinetic, Safety and Pharmacodynamic of MW032 and Xgeva® in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mabwell (Shanghai) Bioscience Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mabwell (Shanghai) Bioscience Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind and parallel group study to compare the pharmacokinetic, safety&#xD;
      and pharmacodynamic of MW032 and Xgeva® in healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I, single center, randomized, double-blind and parallel group clinical trial.&#xD;
&#xD;
      The primary objective is to assess the pharmacokinetic similarity of single and subcutaneous&#xD;
      injections of MW032 and Xgeva® in healthy volunteers.&#xD;
&#xD;
      The secondary objective are to assess the Clinical safety and immunogenicity similarity of&#xD;
      single and subcutaneous injections of MW032 and Xgeva® in healthy volunteers.&#xD;
&#xD;
      At the same time, preliminary evaluate the pharmacodynamic similarity between MW032 and&#xD;
      Xgeva®.&#xD;
&#xD;
      Subjects would receive a single 120mg（1.7mL）of MW032 or Xgeva® through subcutaneous&#xD;
      injection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 25, 2019</start_date>
  <completion_date type="Actual">February 26, 2020</completion_date>
  <primary_completion_date type="Actual">January 10, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC0-t )</measure>
    <time_frame>Day0-Day161</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum serum concentration (Cmax)</measure>
    <time_frame>Day0-Day161</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events(AE)</measure>
    <time_frame>Day0-Day161</time_frame>
    <description>The adverse medical events that occur after the clinical trial subjects receive the test drug do not necessarily have a causal relationship with the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum CTX1</measure>
    <time_frame>Day0-Day161</time_frame>
    <description>CTX1 is a serum type I collagen C-terminal peptide to detect the bone metastasis events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Bone Tumor</condition>
  <arm_group>
    <arm_group_label>MW032</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MW032 injection (120mg) by subcutaneous injection once on the first day of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xgeva®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xgeva® injection (120mg) by subcutaneous injection once on the first day of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MW032</intervention_name>
    <description>Subjects would receive a single 120mg (1.7 mL) of MW032 through subcutaneous injection, on the first day of treatment.</description>
    <arm_group_label>MW032</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xgeva®</intervention_name>
    <description>Subjects would receive a single 120mg (1.7 mL) of Xgeva® through subcutaneous injection, on the first day of treatment.</description>
    <arm_group_label>Xgeva®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-65 years old (including 18 and 65 years old), healthy male subjects.&#xD;
&#xD;
          -  Body mass index (BMI) within the range 19-28kg/m2.&#xD;
&#xD;
          -  History, physical examination, laboratory tests and test related items of inspection&#xD;
             were normal or mildly abnormal clinically insignificant.&#xD;
&#xD;
          -  Volunteered to participate in this clinical trial, capable of giving written informed&#xD;
             consentan.&#xD;
&#xD;
          -  The subject (including the subject's partner) takes effective contraceptive measures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Nervous/mental, respiratory system, cardiovascular system, digestive system, blood and&#xD;
             lymphatic system, endocrine system, skeletal and muscular system diseases, liver and&#xD;
             kidney dysfunction, or any other diseases and physiological conditions that may affect&#xD;
             the results of the study.&#xD;
&#xD;
          -  Occurred or suffering from osteomyelitis or ONJ (mandibular necrosis) previously.&#xD;
&#xD;
          -  Clinical laboratory abnormalities of clinical significance, or other clinical findings&#xD;
             suggest clinically significant following diseases (including, but not limited to the&#xD;
             gastrointestinal tract, kidney, liver, nerve, blood, endocrine, cancer, lung, immune,&#xD;
             mental or cardiovascular disease).&#xD;
&#xD;
          -  Subject has viral hepatitis (including hepatitis B and hepatitis C), AIDS antibodies,&#xD;
             and Treponema pallidum antibodies.&#xD;
&#xD;
          -  Those who have used the following drugs within 1 month or 5 half-lives (whichever is&#xD;
             longer) before participating in this study, including but not limited to:&#xD;
             estrogen-containing contraceptives, bisphosphonates, fluoride, hormone replacement&#xD;
             Treatment (ie tibolone, estrogen, estrogen-like compounds, such as raloxifene),&#xD;
             calcitonin, strontium, parathyroid hormone or its derivatives, vitamin D supplements&#xD;
             (&gt;1000 IU/day), corticosteroids (inhaled or topical corticosteroids can be used 2&#xD;
             weeks before enrollment), anabolic hormone drugs, calcitriol, diuretics.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PKUCare Luzhong Hospital</name>
      <address>
        <city>Zibo</city>
        <state>Shandong</state>
        <zip>255400</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Denosumab</keyword>
  <keyword>Biosimilar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

